Special Session

Presidential Symposium II - EL02 - Biologic/Genetic Markers are the Only Method to Select Patients for Combined RT and Immunotherapy

9/15/2019
10:15 AM - 11:45 AM
Location: Room W176

Session Type: Special Session
0.00 AMA PRA Category 1 Credits™

This session will explore the rapidly evolving clinical arena of combining radiation and immunotherapy and the potential role for various emerging biologic and/or genetic markers to aide rational patient selection.

The objectives of this session are to:
1.Describe the current state of affairs of existing biomarkers (intratumoral, peripheral/blood-based, genetic, immunologic, and imaging-based)
2.Describe the current controversies and challenges for our field in terms of biomarker discovery, validation and clinical application/integration
3.Discuss future strategies to refine patient selection for radiation-immunotherapy combinations by integrating exploratory biomarkers into clinical trial design

Following an introduction to the above concepts - an interactive case-based small group discussion will ensue. A broad spectrum of clinical vignettes highlighting real-world scenarios ranging from the localized/definitive treatment setting to the diffusely metastatic/palliative setting will serve to consolidate educational themes, highlight controversies/current gaps in knowledge and inspire future research/progress in our field.

Presentations:

Ariel Marciscano, MD

Memorial Sloan Kettering Cancer Center

Disclosure:
Employment
Memorial Sloan Kettering Cancer Center: Employee

Presentation(s):

Send Email for Ariel Marciscano

David Kirsch, MD, PhD, FASTRO

Duke University Medical Center

Disclosure:
Employment
Duke University Medical Center : Professor : Employee

Compensation
Lumicell Diagnostics: Advisory Board: Consultant;
Merck: Research Grants;
XRAD Therapeutics: Research Support; Stock

Ownership
Lumicell Diagnostics: Patent/License Fees/Copyright: Stock: Stock Options;
XRAD Therapeutics : Stock

Presentation(s):

Send Email for David Kirsch

Heather McGee, MD, PhD

Icahn School of Medicine at Mount Sinai

Disclosure:
Employment
MOUNT SINAI RADIATION ONCOLOGY: RESIDENT: Employee

Compensation
Society for Immunotherapy of Cancer "Sparkathon": Travel Expenses

Biography:
I was raised in Davis, California and attended the University of California, Berkeley, where I studied Biochemistry & Molecular Biology. After graduation, I moved to England and received a M. Phil in Immunology at the University of Cambridge. I then completed my MD/PhD in Immunobiology at Yale University, where I worked with Dr. Richard Flavell to study the role of the cytokine interleukin-22 in wound healing and tissue repair. During my radiation oncology residency at Mount Sinai, I served on the planning committee for the ASTRO/SITC/NCI Science Workshop on “Incorporating Radiation Oncology into Immunotherapy” and was a member of the first annual SITC “Sparkathon” for Young Investigators in Immunotherapy. I am looking forward to pursuing a career as a physician-scientist and starting my own research program.

Presentation(s):

Send Email for Heather McGee


Assets

Presidential Symposium II - EL02 - Biologic/Genetic Markers are the Only Method to Select Patients for Combined RT and Immunotherapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Presidential Symposium II - EL02 - Biologic/Genetic Markers are the Only Method to Select Patients for Combined RT and Immunotherapy